Abstract Library

#4403 Ki-67 index cut-off values and survival prognostication in neuroendocrine neoplasms: Machine learning-based insights

Introduction: The current grading system for gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) is based on Ki-67 index and/or mitotic rate. By definition, high-grade NEN (neuroendocrine tumour grade 3 [NET G3] and neuroendocrine carcinoma [NEC]) have a Ki-67 >20%, while NET G1 have a Ki-67

Conference:

Presenting Author:

Authors: Melhorn P, Berchtold L, Mazal P, Raderer M, Kiesewetter B,

Keywords: neuroendocrine neoplasm, prognosis, ki-67 index,

#3914 Mediastinal neuroendocrine tumor with heart metastasis response to immunotherapy

Introduction: Mediastinal tumor is unusual, representing 0.2 to 1.5% of tumors in human, mediastinal neuroendocrine tumor even rare.

Conference:

Presenting Author: Cai W

Authors: Cai W, Chen G, Ge W, Hu H,

Keywords: Mediastiunum, NET G2, Immunotherapy,

#3866 Treatment efficacy in 212 metastatic small intestinal neuroendocrine tumor grade 2 patients

Introduction: Small intestinal neuroendocrine tumors (Si-NET) are frequently studied as a single entity, irrespective of their grade, which is known to influence prognosis.

Conference:

Presenting Author: Papantoniou D

Authors: Papantoniou D, Grönberg M, Thiis-Evensen E, Sorbye H, Landerholm K,

Keywords: small intestinal neuroendocrine tumor, grade 2, somatostatin analogues, PRRT, Ki-67, somatostatin-receptor negative,

#3776 Long-term effects of peptide receptor radionuclide therapy (PRRT) used as first-line treatment of GEP-NET – A single centre experience

Introduction: Peptide receptor radionuclide therapy (PRRT) is a well-recognized treatment option for inoperable/metastatic somatostatin receptor-positive neuroendocrine tumors (NET) currently according to guidelines used as second or third line of treatment.

Conference:

Presenting Author:

Authors: Opalinska M, Sowa-Staszczak A, Kurzyńska A, Morawiec-Sławek K, Olearska H,

Keywords: PRRT, first-line treatment, outcome, GEP-NET, NET,

#3745 Prediction of disease recurrence in patients after complete PanNET G2 resection

Introduction: The number of pancreatic neuroendocrine tumors (PanNETs) detected has been increasing over the past decade. Surgical resection is the only potentially curative treatment for PanNETs, but the risk factors for recurrence are not fully understood, which is of clinical value especially for G2 PanNETs due to their high heterogeneity.

Conference:

Presenting Author:

Authors: Opalinska M, Olearska H, Sowa-Staszczak A, Morawiec-Sławek K, Kurzyńska A,

Keywords: PanNET G2, recurrence risk, NET G2, surgery, PanNET,